Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib

Show full item record



Permalink

http://hdl.handle.net/10138/297942

Citation

Peltola , K J , Penttilä , P , Rautiola , J , Joensuu , H , Hänninen , E , Ristimäki , A & Bono , P 2017 , ' Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib ' , Clinical Genitourinary Cancer , vol. 15 , no. 4 , pp. 487-494 . https://doi.org/10.1016/j.clgc.2017.01.021

Title: Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib
Author: Peltola, Katriina Johanna; Penttilä, Patrick; Rautiola, Juhana; Joensuu, Heikki; Hänninen, Erkki; Ristimäki, Ari; Bono, Petri
Contributor: University of Helsinki, Department of Oncology
University of Helsinki, Department of Oncology
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Heikki Joensuu / Principal Investigator
University of Helsinki, HUSLAB
University of Helsinki, Department of Pathology
University of Helsinki, University of Helsinki
Date: 2017-08
Language: eng
Number of pages: 8
Belongs to series: Clinical Genitourinary Cancer
ISSN: 1558-7673
URI: http://hdl.handle.net/10138/297942
Abstract: Prognostic markers for treatment selection in metastatic renal cell carcinoma (mRCC) do not exist. This study evaluates c-Met expression in sunitinib-treated patients with mRCC, and elucidates its role as a possible marker for survival. c-Met expression was analyzed from 137 formalin-fixed paraffin-embedded tumor samples using a validated immunostaining protocol. High c-Met expression is associated with poor survival in patients with mRCC treated with sunitinib. Background: Treatment of patients with metastatic renal cell carcinoma (mRCC) has improved substantially since the introduction of targeted therapies, but no predictive biomarkers are available. The proto-oncogene c-Met is involved in tumor angiogenesis, development, and metastasis. The main objective was to evaluate c-Met expression in sunitinibtreated patients with mRCC, including patients with bone metastases. Methods: c-Met expression was analyzed from 137 formalin-fixed paraffin-embedded tumor samples using a validated immunostaining protocol. Results: Patients with low c-Met expression (n = 78) had longer progression-free survival (PFS) (median 14.3 vs. 6.5 months; P
Subject: Angiogenesis inhibitor
c-Met inhibitor
mRCC
Prognostic marker
HEPATOCYTE GROWTH-FACTOR
CANCER
CABOZANTINIB
TUMORS
INVASION
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S155876731730037X_main.pdf 1009.Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record